Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px

Person › Details

Anke Linnartz (MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR))

Linnartz, Anke (MorphoSys 201611– Head Corp Communications + IR before Gerresheimer + Demag Cranrd + GEA + MIS)

	Organisation	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Group	MorphoSys (Group)
	Former/major organisation	Gerresheimer (Group)
	Product	public relations / investor relations / marcom (services)
	Product 2	Ylanthia® antibody technology

Record changed: 2018-02-20

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Anke Linnartz

[1] MorphoSys AG. (10/23/17). "Press Release: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL". Planegg....
[2] MorphoSys AG. (8/3/17). "Press Relase: MorphoSys Reports Significant Progress in Its Therapeutic Programs in Second Quarter of 2017". Planegg....
[3] MorphoSys AG. (7/13/17). "Press Release: MorphoSys Announces that Its Licensee Janssen Has Received US FDA Approval for Tremfya (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis". Planegg-Martinsried....
[4] MorphoSys AG. (6/2/17). "Press Release: MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL". Planegg....
[5] MorphoSys AG. (3/6/17). "Press Release: MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer’s Disease". Planegg-Martinsried....
[6] MorphoSys AG. (3/3/17). "Press Release: MorphoSys Announces that Its Licensee Janssen Has Reported New Data From Two Phase 3 Studies of Guselkumab in Plaque Psoriasis". Planegg....
[7] MorphoSys AG. (2/15/17). "Press Release: District Court Grants MorphoSys's Request to Add Second Patent in Lawsuit with Janssen Biotech and Genmab". Planegg....
[8] MorphoSys AG. (2/10/17). "Press Release: MorphoSys to Present at Upcoming Conference". Planegg....
[9] MorphoSys AG. (1/12/17). "Press Release: MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients with Type 2 Diabetes". Planegg....
[10] MorphoSys AG. (1/3/17). "Press Release: MorphoSys to Present at Upcoming Investor Conferences". Planegg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)